Factors contributing to the rise of buprenorphine misuse: 2008-2013

Drug and Alcohol Dependence

Volumn 142, Issue , 2014, Pages 98-104

  Cicero, Theodore J ^a   Ellis, Matthew S ^a   Surratt, Hilary L ^b   Kurtz, Steven P ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Buprenorphine misuse; Heroin; Opioid misuse; Self treatment of opioid dependence

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; METHADONE; OPIATE; NARCOTIC ANTAGONIST;

ADULT; ANALGESIA; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG DEPENDENCE TREATMENT; DRUG MISUSE; DRUG PREFERENCE; DSM-IV; FEMALE; HUMAN; INTRAVENOUS DRUG ABUSE; LAW ENFORCEMENT; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; SELF MEDICATION; SEMI STRUCTURED INTERVIEW; INTERVIEW; MOTIVATION; PSYCHOLOGY; QUALITATIVE RESEARCH;

ADULT; BUPRENORPHINE; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; MOTIVATION; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; QUALITATIVE RESEARCH;

EID: 84905565404     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.06.005     Document Type: Article

References (41)

1. Aalto M., Halme J., Visapää J.P., Salaspuro M. Buprenorphine misuse in Finland. Subst. Use Misuse 2007, 42:1027-1028.
2. Alford D.P., LaBelle C.T., Kretsch N., Bergeron A., Winter M., Botticelli M., Samet J.H. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch. Int. Med. 2011, 171:425-431.
3. Alho H., Sinclair D., Vuori E., Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007, 88:75-78.
4. Auriacombe M., Fatséas M., Dubernet J., Daulouède J.P., Tignol J. French field experience with buprenorphine. Am. J. Addict. 2004, 13(Suppl. 1):S17-S28.
5. Bell J. The global diversion of pharmaceutical drugs: opiate treatment and the diversion of pharmaceutical opiates: a clinician's perspective. Addiction 2010, 105:1531-1537.
6. Bell J.R., Butler B., Lawrance A., Batey R., Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend. 2009, 104:73-77.
7. Bickel W.K., Stitzer M.L., Bigelow G.E., Liebson I.A., Jasinski D.R., Johnson R.E. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J. Pharmacol. Exp. Ther. 1988, 247:47-53.
8. Carrieri M.P., Amass L., Lucas G.M., Vlahov D., Wodak A., Woody G.E. Buprenorphine use: the international experience. Clin. Infect. Dis. 2006, 43(Suppl. 4):S197-S215.
9. Center for Substance Abuse Treatment (CSAT) Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction-A Treatment Improvement Protocol (TIP40). Series 40 2004, Center for Substance Abuse Treatment (CSAT), Rockville, MD, (DHHS Publication No. SMA 04-3939).
10. Chiang C.N., Hawks R.L. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003, 70:S39-S47.
11. Cicero T.J., Dart R.C., Inciardi J.A., Woody G.E., Schnoll S., Muñoz A. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS). Pain Med. 2007, 8:157-170.
12. Cicero T.J., Ellis M.S., Surratt H.L., Kurtz S.P. Factors influencing the selection of hydrocodone and oxycodone as primary opioids in substance abusers seeking treatment in the United States. Pain 2013, 154:2639-2648.
13. Cicero T.J., Surratt H., Inciardi J.A., Munoz A. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol. Drug Saf. 2007, 16:827-840.
14. Comer S.D., Sullivan M.A., Vosburg S.K., Manubay J., Amass L., Cooper Z.D., Saccone P., Kleber H.D. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction 2010, 105:709-718.
15. Degenhardt L., Randall D., Hall W., Law M., Butler T., Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend. 2009, 105:9-15.
16. Donaher P.A., Welsh C. Managing opioid addiction with buprenorphine. Am. Fam. Physician 2006, 73:1573-1578.
17. Drug Addiction Treatment Act of, 2000, Public Law 106-310, title XXXV, section 3502(a), 2000. Available at http://buprenorphine.samsha.gov/data.html. [accessed 2/20/14].
18. Drug Enforcement Administration, Office of Diversion Control National Forensic Laboratory Information System (NFLIS), Special Report: Methadone and Buprenorphine, 2003-2008 2009, Available online at 〈www.deadiversion.usdoj.gov/nflis/methadone_buprenorphine_srpt.pdf〉 (accessed 2/20/14).
19. Fiellin D., O'Connor P. Clinical Practice. Office-based treatment of opioid-dependent patients. N. Engl. J. Med. 2002, 347:817-823.
20. Greenwald M.K., Johanson C.E., Moody D.E., Woods J.H., Kilbourn M.R., Koeppe R.A., Schuster C.R., Zubieta J.K. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 2003, 28:2000-2009.
21. Guichard A., Lert F., Calderon C., Gaigi H., Maguet O., Soletti J., Brodeur J.M., Richard L., Benigeri M., Zunzunegui M.V. Illicit drug use and injection practices among drug users on methadone and buprenorphine maintenance treatment in France. Addiction 2003, 98:1585-1597.
22. Johnson R.E., Jaffe J.H., Fudala P.J. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992, 267:2750-2755.
23. Lavonas E.J., Severtson S.G., Martinez E.M., Bucher-Bartelson B., Le Lait M.C., Green J.L., Murrelee L.E., Cicero T.J., Kurtz S.P., Rosenblum A., Surratt H.L., Dart R.C. Abuse and diversion of buprenorphine sublingual tablets and film. J. Subst. Abuse Treat. 2014, 47:27-34.
24. Ling W., Charuvastra C., Collins J.F., Batki S., Brown L.S., Kintaudi P., Wesson D.R., McNicholas L., Tusel D.J., Malkerneker U., Renner J.A., Santos E., et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998, 1998:475-486.
25. Mammen K., Bell J. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. Expert Opin. Pharmacother. 2009, 10:2537-2544.
26. Mendelson J., Jones R.T. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?. Drug Alcohol Depend. 2003, 70(Suppl. 2):S29-S37.
27. Peterson J.A., Schwartz R.P., Mitchell S.G., Reisinger H.S., Kelly S.M., O'Grady K.E., Brown B.S., Agar M.H. Why don't out-of-treatment individuals enter methadone treatment programmes?. Int. J. Drug Policy 2010, 21:36-42.
28. Reckitt Benckiser Pharmaceuticals Inc. Highlights of Prescribing Information 2014, 〈http://www.suboxone.com/pdfs/suboxonepi.pdf〉 (accessed 5/12/14).
29. Schuster C.R. History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs. Drug Alcohol Depend. 2006, 83(Suppl. 1):S8-S14.
30. Schwartz R.P., Kelly S.M., O'Grady K.E., Mitchell S.G., Peterson J.A., Reisinger H.S., Agar M.H., Brown B.S. Attitudes toward buprenorphine and methadone among opioid-dependent individuals. Am. J. Addict. 2008, 17:396-401.
31. Stoller K.B., Bigelow G.E., Walsh S.L., Strain E.C. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl.) 2001, 154:230-242.
32. Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network (DAWN) National Estimates of Drug-Related Emergency Department Visits 2004-2009 2011, Available online at 〈dawninfo.samhsa.gov〉 (accessed 2/20/14).
33. Substance Abuse and Mental Health Services Administration (SAMHSA):2014 Center for Substance Abuse Treatment (CSAT), undated. Buprenorphine. Available from: http://buprenorphine.samhsa.gov.[accessed 2/20/14].
34. Sullivan L.E., Moore B.A., Chawarski M.C., Pantalon M.V., Barry D., O'Connor P.G., Schottenfeld R.S., Fiellin D.A. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J. Subst. Abuse Treat. 2008, 35:87-92.
35. United States Department of Justice, National Drug Intelligence Center (NDIC) Misuse of Buprenorphine-Related Products, SENTRY Drug Alert Watch, February 22, 2011 2011, Available online at 〈www.justice.gov/ndic/pubs44/44054/sw0009p.pdf〉 (accessed 2/20/14).
36. Vidal-Trecan G., Varescon I., Nabet N., Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend. 2003, 69:175-181.
37. Walsh S.L., Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003, 70(Suppl. 2):S13L S27.
38. Walsh S.L., Preston K., Stitzer M., Cone E., Bigelow G. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther. 1994, 55:569-580.
39. Yokell M.A., Zaller N.D., Green T.C., Rich J.D. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr. Drug Abuse Rev. 2011, 4:28-41.
40. Zaller N.D., Bazazi A.R., Velazquez L., Rich J.D. Attitudes toward methadone among out-of-treatment minority injection drug users: implications for health disparities. Int. J. Environ. Res. Public Health 2009, 6:787-797.
41. Wish E.D., Artigiani E., Billing A., Hauser W., Hemberg J., Shiplet M., DuPont R.L. The emerging buprenorphine epidemic in the United States. J. Addict. Dis. 2012, 31:3-7.